Related Experiment Video
Updated: Dec 5, 2025
Intramyocardial Transplantation of MSC-Loading Injectable Hydrogels after Myocardial Infarction in a Murine Model
Published on: September 20, 2020
Hybrid myocardial revascularization
Yugal Kishore Mishra1, Jatin Yadav1
1Department of Cardiac Surgery, Fortis Escorts Heart Institute, Okhla Road, New Delhi, 110025 India.
Insights
Hybrid myocardial revascularization (HMR) offers a promising alternative for advanced coronary artery disease (CAD) patients, combining bypass surgery and stenting with similar outcomes to traditional bypass surgery but faster recovery.
Area of Science:
- Cardiovascular Surgery
- Interventional Cardiology
- Medical Technology
Background:
- Coronary artery disease (CAD) management involves a choice between coronary artery bypass grafting (CABG) for long-term benefits and percutaneous coronary intervention (PCI) for reduced procedural risks.
- Hybrid myocardial revascularization (HMR) integrates CABG and PCI to balance the advantages and disadvantages of each approach.
- HMR strategies include CABG followed by PCI, PCI followed by CABG, or simultaneous procedures in a hybrid suite.
Purpose of the Study:
- To evaluate the feasibility, safety, and efficacy of HMR compared to standard CABG.
- To assess the clinical outcomes and adverse events associated with HMR in patients with multivessel CAD.
- To determine if HMR offers advantages in terms of rehabilitation and return to daily life.
Main Methods:
- The POL-MIDES trial, a randomized controlled trial, compared HMR (CABG first) with standard CABG.
- Feasibility of HMR was assessed, along with rates of conversion to standard CABG.
- One-year all-cause mortality and major adverse clinical event (MACE)-free survival were compared between groups.
Main Results:
- HMR was feasible in 93.9% of patients, with a 6.1% conversion rate to standard CABG.
- At one year, HMR and CABG showed similar all-cause mortality (2% vs. 2.9%) and MACE-free survival (89.8% vs. 92.2%).
- Observational studies indicate HMR has minimal perioperative mortality and morbidity, with no increased bleeding risk, and offers faster patient recovery.
Conclusions:
- Hybrid myocardial revascularization is a viable and promising treatment for high-risk CAD patients.
- HMR, utilizing minimally invasive surgery and PCI, can provide optimal revascularization of critical coronary arteries.
- This technique presents a valuable alternative for patients with high operative risk undergoing standard surgery.
Background:
In patients with advanced coronary artery disease (CAD), coronary artery bypass grafting (CABG) is associated with improved long-term outcomes while percutaneous coronary intervention (PCI) is associated with lower periprocedural complications. A new approach has emerged in the last decade that attempts to reap the benefits of bypass surgery and stenting while minimizing the shortcomings of each approach, hybrid myocardial revascularization (HMR).Three strategies for timing of the hybrid revascularization exists, each with their own inherent advantages and shortcomings: (1) CABG followed by PCI, (2) PCI followed by CABG, or (3) simultaneous CABG + PCI in a hybrid suite.
Studies:
The results of the first randomized control trial comparing HMR (CABG first) and standard CABG, POL-MIDES (Prospective Randomized PilOt Study EvaLuating the Safety and Efficacy of Hybrid Revascularization in MultIvessel Coronary Artery DisEaSe), show HMR was feasible for 93.9% of patients whereas conversion to standard CABG was required for 6.1%. At 1 year, both groups had similar all-cause mortality (CABG 2.9% vs. HMR 2%) and major adverse clinical event (MACE)-free survival rates (CABG 92.2% vs. HMR 89.8%). Results of observational and comparative studies show that minimally invasive HMR procedures in patients with multivessel CAD carry minimal perioperative mortality risk and low morbidity and do not increase the risk of postoperative bleeding. The advantage they offer in comparison to classical surgical revascularization is indeed faster rehabilitation and patient's return to normal life.
Conclusion:
Hybrid myocardial revascularization has been developed as a promising technique for the treatment of high-risk patients with CAD. Hybrid revascularization using minimally invasive surgical techniques combined with PCI offers to a part of patients an advantage of optimal revascularization of the most important artery of the heart, together with adequate myocardial revascularization in a relatively delicate way. Indeed, to patients with high operative risk of standard surgery, it offers an alternative which should be considered carefully.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy